MEdPACTO

Medpacto takes part in BIO 2023… will actively engage in discussions regarding the commercialization of its pipelines, exploring opportunities for out-licensing

Seong-jin Kim, the CEO of MedPacto, unveils innovative new drug candidate at the Korean Society for Bone and Mineral Research

MedPacto, successfully completed the Type C meeting with the U.S. FDA for its global Phase2b/3 clinical trial of Vactosertib + Keytruda combination therapy

Vactosertib in combination with KEYTRUDA® (pembrolizumab) for colorectal cancer patients reported a mOS of 15.8 months 

MedPacto and Theragen Etex have come together to expand the anti-cancer drug business

MedPacto Announces Poster Presentation on Combination Treatment of Vactosertib with PRMT5 in Pancreatic Cancer at the 2023 AACR Annual Meeting

MedPacto participates in the '2023 BIO-Europe Spring'... accelerating commercialization including out-licensing

MedPacto has obtained a domestic patent for the manufacture of Vactosertib

MedPacto receives IND approval from the Ministry of Food and Drug Safety to evaluate the safety and efficacy of Vactosertib as a single agent in patients with osteosarcoma

The efficacy of the combination treatment of Vactosertib with PRMT5 in pancreatic cancer was published in an international journal Cell Death and Disease (IF: 8.469)

MedPacto, identified the mechanism of action of the protein associated with the regulation of spermatogonial stem cell self-renewal

MedPacto hires global healthcare expert Namchol Park, as the Executive Vice President(EVP)

MedPacto receives U.S. FDA Fast Track designation for vactosertib for the treatment of metastatic osteosarcoma

Vactosertib research paper is published in ‘Cancers’, an international academic journal indexed in SCIE

MedPacto granted a European patent for their diagnostic kit detecting cancer cells in the blood

MedPacto discovers the world's first mechanism of liver metastasis in gastric cancer cells

MedPacto, Announces the formation of the Clinical Advisory Board for speeding up its new drug development and out-licensing

Once at home on palliative care, a pediatric patient with osteosarcoma enjoys an active return to school and a prolonged progression-free period while on Vactosertib monotherapy.

Seongjin Kim, CEO of MedPacto, meets with Maryland Governor Larry Hogan

MedPacto, Receives Rare Pediatric Disease Designation from the U.S. FDA for osteosarcoma patients

MedPacto presents interim Phase 1b clinical results for Vactosertib in combination with FOLFOX at AACR Special Conference on Pancreatic Cancer

MedPacto receives IND approval from FDA to evaluate the safety and efficacy of Vactosertib as a single agent in patients with osteosarcoma

MedPacto, announces IND submission to U.S. FDA to evaluate safety and efficacy of Vactosertib as a single agent in patients with osteosarcoma.

MedPacto to present the abstract about the combination study of Vactosertib in pancreatic cancer at the American Society of Clinical Oncology Annual Meeting

SeongJin Kim, CEO of MedPacto, named keynote peaker for BioKorea 2022

MedPacto announces execution of investigator-initiated clinical trials for combination therapy in gastric cancer patients

MedPacto Announces Execution of a collaborative study Agreement for ‘Cancer Diagnostic Kit’ with Gangnam Severance Hospital   

MedPacto hires global clinical expert Timothy R. Allen, Executive Vice President(EVP)

Seongjin Kim, CEO of MedPacto, defined the MOA of the chemoresistance-associated protein and potential predictive biomarker

UH Seidman Cancer Center to Launch First-Ever Trial of NK Therapy and Vactosertib in Treating Colorectal Cancer and Hematological Malignancies

MedPacto Announces Execution of a Clinical Trial Agreement for a NK Cell Combination Trial for Colorectal Patients

MedPacto, HITS team up for AI-based drug development

MedPacto to release the clinical trial design of combination study in patients with metastatic pancreatic ductal adenocarcinoma at ASCO GI

MedPacto, advance procedures for the global Phase 3 combination trial for the colorectal patients are going smoothly

MedPacto Announces Clinical Collaboration with MSD to Evaluate Vactosertib, an Investigational TGF-β Type I Receptor Inhibitor, in combination with KEYTRUDA® (pembrolizumab) in a Phase 3 Trial with Registrational Intent

MedPacto to test Vactosertib for treating NSCLC

[ASCO 2020 ④] MedPacto's Vactosertib combo treatment for desmoid tumors proved safe

Stock issuance

Keytruda Combination Trial Application Approval followed by Another Approval for the Vactosertib + Durvalumab Combination Trial Application

Stock issuance

MedPacto Announces Clinical Collaboration with MSD to Evaluate Vactosertib, an Investigational TGF-β Type I Receptor Inhibitor, in combination with KEYTRUDA® (pembrolizumab)

MedPacto Announces Immuno-Oncology Clinical Trial Collaboration with AstraZeneca

Announcement of the closing date of shareholder list

Stock issuance

Stock issuance

Stock issuance

Temporary meeting of the board of directors

The MedPacto Inc. board has appointed Dr. Seong-Jin Kim as a co-chief executive officer

Announcement: 3rd annual general meeting of stockholders

Collaboration with ANRT

Announcement: 2nd annual general meeting of stockholders

Temporary meeting of the board of directors

Announcement: An annual general meeting of stockholders

National OncoVenture (NOV) announces the support of development of MedPacto’s leading anticancer drug candidate, TEW-7197